Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | European Journal of Clinical Pharmacology - incl. option to publish open access (Editorial Board)

European Journal of Clinical Pharmacology

European Journal of Clinical Pharmacology

Coordinating Editor: Rune Dahlqvist

ISSN: 0031-6970 (print version)
ISSN: 1432-1041 (electronic version)

Journal no. 228

$199.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 12 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Coordinating Editor

Rune Dahlqvist
Division of Clinical Pharmacology
University Hospital
90185 Umeå

E-mail: Rune.Dahlqvist@pharm.umu.se

Managing Editors
Uwe Fuhr, Cologne
Emilio J. Sanz, La Laguna
David J.P. Williams, Dublin

Reviews Editor
Uwe Fuhr, Cologne

Advisory Editors
Karel Allegaert, Leuven 
Junichi Azuma, Osaka
Janne Backman, Helsinki 
Julio R. Benítez, Badajoz
Joseph S. Bertino Jr, Albany
Maurizio Bonati, Milan
Alasdair M. Breckenridge, Liverpool
Ingolf Cascorbi, Kiel
Imtiaz Choonara, Derby
Balram Chowbay, Singapore
Fan K. Chung, London
Uwe Christians, Denver
Marja-Liisa Dahl, Stockholm
Vita Dolzan, Ljubljana
Adrienne Einarson, Toronto
Johan Fastbom, Stockholm
Robin E. Ferner, Birmingham
Alberg Figueras, Barcelona
Sarah Foley, Cork
Sebstian Frechen, Köln
Takahisa Furuta, Hamamatsu
Andrea Gaedigk, Kansas City
Silvio Garattini, Milan
Walter E. Haefeli, Heidelberg
Staffan Hägg, Linköping
Job Harenberg, Mannheim
Martin Hellmich, Köln
Georg Hempel, Münster
Christoph Hiemke, Mainz
Nick Holford, Auckland
Kalle Hoppu, Helsinki
Alexander Jetter, Zurich
Frieder Keller, Ulm
Stephan Krähenbühl, Basel
Joan R. Laporte, Barcelona
Andreas Lindauer, Oss
Jörn Lötsch, Frankfurt
Arduino A. Mangoni, Bedford Park
Patricia McGettigan, London
John Miners, Adelaide
Klaus Mörike, Tübingen
Nicola Montanaro, Bologna
Jean-Louis Montastruc, Toulouse
Nicholas Moore, Bordeaux
Domenico Motola, Bologna
Pertti J. Neuvonen, Helsinki
Hedvig M.E. Nordeng, Oslo
Stefan Oswald, Greifswald
Roberto Raschetti, Roma
Cristín Ryan, Dublin
Laura J. Sahm, Cork
Jörn Schneede, Umeå
Werner Siegmund, Greifswald
Folke Sjöqvist, Huddinge
Olav Spigset, Trondheim
Edoardo Spina, Messina
Julia C. Stingl, Bonn
John Stinson, Crumblin
J.J. Swen, Leiden
Petra Thürmann, Wuppertal
Dietmar Trenk, Bad Krozingen
Ellen Vinge, Lund
Susanna M. Wallerstedt, Gothenburg
Tom Walley, Liverpool
Matthew Walters, Glasgow
William S. Waring, Edinburgh
Martin Wehling, Mannheim
Björn Wettermark, Stockholm
Nick J. White, Oxford
Ken W. Woodhouse, Cardiff
Ümit Yasar, Ankara
Hong-Hao Zhou, Changsha













Read this Journal on Springerlink

For authors and editors

  • Journal Citation Reports®
    2017 Impact Factor
  • 2.679
  • Aims and Scope

    Aims and Scope


    The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.

    Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.

    Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves

    • a compound that is interesting and new in some basic or fundamental way, or
    • methods that are original in some basic sense, or
    • a highly unexpected outcome, or
    • conclusions that are scientifically novel in some basic or fundamental sense.

    Straightforward descriptive data in drug utilization will only be considered if more than one geographical area is studied and if a scientific hypothesis is tested or an intervention carried out. Descriptive data in drug utilization can however be quite useful in a more local setting. Again, if conceptually new methods, analysis, or ways of reasoning are involved, this would elicit greater interest from the international scientific community. In such a case, we would welcome submission to the EJCP and evaluate the paper according to standard procedures.

    The Journal also accepts review articles on various topics related to drug action in man. Debate on controversial issues is also encouraged, usually in the form of a letter to the editor that comments on a paper published in the Journal. Case reports on new findings or a new understanding of a mechanism of action should usually also be submitted in the form of a letter to the editor.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors


  • Author Academy: Training for Authors
  • Copyright Information

    Copyright Information


    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.

    © Springer-Verlag Berlin Heidelberg

Services for the Journal

Alerts for this journal


Get the table of contents of every new issue published in European Journal of Clinical Pharmacology.